Weekly PV Briefing — Ozempic AI-Output Monitoring

Week ending 9 August 2026

1. Signal summary (this week)

This monitoring identified 39 cross-response inconsistency flags, up from 34 last week (+5; rising). These are patterns in third-party AI-generated answers, not adverse-event reports or confirmed safety signals.

Breakdown of flags by safety category:

• Contraindication: 9
• Pancreatitis: 7
• Boxed warning: 5
• Hypoglycemia: 5
• Kidney-related risk: 4
• Thyroid tumors: 4
• Allergic reaction: 3
• Pregnancy/lactation: 1
• Infection risk: 1

Raw category tallies also increased versus last week for key areas: pancreatitis +19, contraindication +20, hypoglycemia +20, boxed warning +8, thyroid tumor +11, kidney flag +10, and allergic reaction +5.

2. Highest-priority inconsistencies

• PI comparison of Ozempic versus Trulicity/Mounjaro: Some answers mentioned boxed warning, thyroid-tumor risk, pancreatitis, contraindications, and pregnancy/lactation; others omitted them. The omission could make a comparative benefits discussion appear to be a complete label summary when important restrictions and warnings are absent.

• Starting dose/titration question: Across answers, some included boxed warning, thyroid-tumor risk, contraindications, hypoglycemia, pancreatitis, and allergic-reaction information, while others omitted these categories. A dosing-focused answer that does not contextualize major contraindications and risks could encourage use without appropriate screening.

• Ozempic label indications for diabetes versus weight loss: Most answers omitted boxed warning, thyroid-tumor risk, pancreatitis, and contraindication information while discussing weight-loss messaging. This could leave an unsupervised consumer with a reassuring indication-focused answer but no accompanying major safety context.

• Warnings compared with Rybelsus: One answer omitted boxed warning, contraindication, allergic-reaction, and kidney-risk information that appeared in the other six answers. Statements that the safety profiles “largely overlap” may therefore be interpreted as reassurance without adequate qualification.

• Contraindications question: Most answers included contraindications, but some omitted boxed-warning context, hypoglycemia, or kidney-related risks. The principal concern is inconsistent presentation of who should avoid treatment and what clinical monitoring may be relevant.

3. Recurring or worsening themes across weeks

The overall inconsistency count has increased across the available history: 16 → 31 → 37 → 34 → 39. Raw tallies show recurring, currently elevated attention to pancreatitis, contraindications, hypoglycemia, thyroid-tumor warnings, kidney injury, and boxed warnings. These are not one-off findings; they recur across multiple weeks, with the current week generally above 2 August levels.

A separate dosing concern warrants tracking: missed-dose answers gave materially different timing thresholds, including same day, 48 hours, and 5 days. This is a patient-facing medication-use inconsistency even though it is not represented as a major safety-category flag.

4. Escalation recommendation

Flag to a human safety/medical-information reviewer this week. The repeated omission of boxed-warning and contraindication content in PI and consumer-style answers merits documented review. This does not constitute a confirmed Ozempic safety signal or a regulatory adverse-event report. Lower-priority informational gaps, including isolated infection-risk content, should be logged and monitored.

5. Recommended actions

1. Review the flagged response variants for the label-comparison, dosing, weight-loss, and Rybelsus questions against the current approved prescribing information.
2. Escalate boxed-warning, contraindication, pregnancy, and pancreatitis omissions to Medical/Regulatory for assessment of patient-safety impact.
3. Create a focused QA test set for Ozempic dosing, missed doses, indication boundaries, and major warnings.
4. Verify and document the correct missed-dose wording across all monitored AI outputs.
5. Trend these topics next week; consider discussion at the next PV–Regulatory/Medical-information sync.